MG
BMRN icon

Mather Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mather Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5K Buy
+363
New +$21.2K ﹤0.01% 1272
2025
Q2 		– Sell
-14
Closed -$990 – 742
2025
Q1 		$990 Buy
14
+11
+367% +$740 ﹤0.01% 1642
2024
Q4 		$197 Sell
3
-17
-85% -$1.14K ﹤0.01% 1700
2024
Q3 		$1.41K Sell
20
-9
-31% -$752 ﹤0.01% 1526
2024
Q2 		$2.53K Buy
29
+13
+81% +$1.08K ﹤0.01% 1823
2024
Q1 		$1.54K Buy
+16
New +$1.43K ﹤0.01% 1578

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mather Group's BMRN Position: Q1 2026 in Review

Mather Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 363 shares worth $20.5K. The stake represents ﹤0.01% of the portfolio and ranks #1272 among its holdings. This is a return to the name: Mather Group previously reported a position in BMRN as recently as Q1 2025.

Mather Group first reported a position in BMRN in Q1 2024 and has held it in 6 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Mather Group held 363 shares of BioMarin Pharmaceuticals worth $20.5K as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Mather Group position in Q1 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1272 holding.
  • Mather Group first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.